BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics to Advance Preclinical Candidates Treating Cancer

BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla for BA3071 and Tislelizumab


  • Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales, retaining rights for candidates in Americas (the US, Canada, and Latin American countries), EU and Japan. BeiGene to get exclusive rights to develop and commercialize the candidates in Asia (Ex- Japan) and ROW and will also be responsible for all clinical development and regulatory submissions
  •  The focus of the agreement is to advance preclinical candidates utilizing Seattle Genetics’ antibody-based technology with expected advancement to clinical trials in H1’20
  • Seattle’s ADC Technology harness the ability of antibodies to deliver cell-killing agents and combines the specificity of mAbs, innovative linker systems, and the power of potent cell-killing agents for the treatment of cancer

Click here to­ read full press release/ article | Ref: Seattle Genetics | Image: Twitter